ArticleOphthalmology and therapy2026
Prevalence and Risk Factors of Ocular Hypertension Following Fluocinolone Acetonide (Iluvien
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this real-life study was to analyze the prevalence and risk factors of ocular hypertension (OHT) after fluocinolone acetonide implant (FAc-I) intravitreal injections in the treatment of macular edema of various etiologies.
methodsThis retrospective, monocentric study included all consecutive patients with ≥ 1 FAc-I injection. The primary endpoint was the occurrence of OHT, defined as intraocular pressure (IOP) of at least 25 mmHg and/or an increase ≥ 10 mmHg from baseline.
resultsA total of 171 eyes of 127 patients were injected with FAc-I for diabetic macular edema (61.4%), post-surgical macular edema (19.9%), uveitis (11.1%), and retinal vein occlusion or radiation maculopathy (7.6%). The prevalence of OHT after FAc-I injections was 24.6% (n = 42) and did not differ among groups according to disease (p = 0.943). In most cases, OHT was successfully treated with topical medication alone (14% of the whole cohort, n = 24, 57% of the hypertonic cases). Selective laser trabeculoplasty (SLT) was used in 12 eyes (7.0%). The rate of incisional IOP-lowering surgery was 3.5% (n = 6). In multivariable analysis, risk factors for OHT included younger age (p = 0.036) and pre-existing OHT or glaucoma (p = 0.034). The positive predictive value for the absence of OHT after DEX-I injections was 80.4%.
conclusionsOHT occurred in approximately one in four eyes after FAc-I injection and was commonly and successfully treated with topical treatment alone or SLT in 95% of the hypertonic cases (40/42). Risk factors for OHT after FAc-I included younger age and pre-existing OHT or glaucoma. Uveitis and retinal vein occlusion were not risk factors for OHT. Previous DEX-I injection seems to be a useful predictive test. Therefore, regular IOP monitoring is essential for all patients receiving FAc-I injections, especially those with risk factors for OHT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.